Memantine
Treatment for Vascular Dementia
Typical Dosage: 5-20 mg daily
Effectiveness
60%
Safety Score
65%
Clinical Trials
4
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
65
DangerousModerateSafe
Treatment Details
Dosage Range
5-20 mg daily
Time to Effect
1-3 months
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
18(Treat 18 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
65%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$500
Side Effect Mgmt:$50
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$2,333
Memantine Outcomes
for Vascular Dementia
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+30%
Common Side Effects
Dizziness
+6%
Headache
+5%
Confusion
+5%
Constipation
+4%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
3 completed trials for Memantine in Vascular Dementia
Local Study of Akatinol Memantine in VaD in Russia
NCT03986424COMPLETEDPHASE3
130 participants
INTERVENTIONAL
Moscow, Russia +3 more
Started: Jan 23, 2018
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT02860338COMPLETED
900 participants
OBSERVATIONAL
Started: Jan 1, 2009
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
NCT01872598COMPLETEDPHASE3
721 participants
INTERVENTIONAL
Varna, Bulgaria +5 more
Started: Jan 1, 2012